Prosight Management, LP Kezar Life Sciences, Inc. Transaction History

Prosight Management, LP

$320 Million
Q2 2024

A detailed history of Prosight Management, LP transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 56,080 shares of KZR stock, worth $459,295. This represents 0.01% of its overall portfolio holdings.

Number of Shares

56,080

Previous 963,598 94.18%

Holding current value

$459,295

Previous $867,000 96.19%

% of portfolio

0.01%

Previous 0.25%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.6 - $0.92 $544,510 - $834,916	-907,518 Reduced 94.18%	56,080 $33,000
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $1.92 Million - $2.52 Million	-2,401,735 Reduced 71.37%	963,598 $867,000
Q4 2023 Feb 14, 2024	SELL	$0.72 - $1.15 $1.01 Million - $1.62 Million	-1,405,466 Reduced 29.46%	3,365,333 $3.2 Million
Q3 2023 Nov 14, 2023	BUY	$1.08 - $2.54 $128,389 - $301,952	118,879 Added 2.56%	4,770,799 $5.68 Million
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $3.35 Million - $4.44 Million	1,451,920 Added 45.37%	4,651,920 $11.4 Million
Q1 2023 May 12, 2023	BUY	$3.13 - $7.31 $4.52 Million - $10.6 Million	1,445,571 Added 82.4%	3,200,000 $10 Million
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $2.73 Million - $3.75 Million	426,530 Added 32.12%	1,754,429 $12.4 Million
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $521,011 - $700,986	65,208 Added 5.16%	1,327,899 $11.4 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $17.13 $4.41 Million - $16.5 Million	962,691 Added 320.9%	1,262,691 $10.4 Million
Q1 2022 May 16, 2022	SELL	$12.3 - $18.33 $738,000 - $1.1 Million	-60,000 Reduced 16.67%	300,000 $4.99 Million
Q4 2021 Feb 14, 2022	SELL	$7.44 - $16.72 $2.01 Million - $4.51 Million	-269,957 Reduced 42.85%	360,000 $6.02 Million
Q3 2021 Nov 12, 2021	SELL	$4.85 - $9.73 $1.91 Million - $3.83 Million	-393,747 Reduced 38.46%	629,957 $5.44 Million
Q2 2021 Aug 13, 2021	BUY	$4.93 - $6.46 $1.35 Million - $1.77 Million	273,394 Added 36.44%	1,023,704 $5.56 Million
Q1 2021 May 14, 2021	BUY	$5.24 - $6.99 $3.93 Million - $5.24 Million	750,310 New	750,310 $4.47 Million
Q4 2020 Feb 12, 2021	SELL	$4.77 - $6.58 $1.75 Million - $2.41 Million	-365,981 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.36 - $5.5 $1.6 Million - $2.01 Million	365,981 New	365,981 $1.77 Million
Q2 2020 Aug 14, 2020	SELL	$3.6 - $7.75 $347,814 - $748,766	-96,615 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$2.77 - $5.75 $618,776 - $1.28 Million	-223,385 Reduced 69.81%	96,615 $421,000
Q4 2019 Feb 14, 2020	BUY	$2.5 - $4.26 $800,000 - $1.36 Million	320,000 New	320,000 $1.28 Million
Q3 2019 Nov 14, 2019	SELL	$3.0 - $7.58 $102,672 - $259,417	-34,224 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.09 - $21.9 $242,648 - $749,505	34,224 New	34,224 $264,000
Q4 2018 Feb 14, 2019	SELL	$20.21 - $32.9 $1.06 Million - $1.72 Million	-52,331 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$15.5 - $21.41 $164,920 - $227,802	10,640 Added 25.52%	52,331 $1.12 Million
Q2 2018 Aug 14, 2018	BUY	$17.15 - $17.79 $715,000 - $741,682	41,691 New	41,691 $721,000

Others Institutions Holding KZR

# of Institutions

Shares Held

39.6M

Call Options Held

3.2K

Put Options Held

700

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $560M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Account

Prosight Management, LP Kezar Life Sciences, Inc. Transaction History